Bioactivity | Azathioprine (BW 57-322) sodium is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces apoptosis[1][3]. |
Invitro | Azathioprine (0-50 μM, 48 hours) sodium can induce severe intracellular GSH depletion with relevant concentrations in both primary rat and human hepatocytes[2]. Cell Viability Assay[2] Cell Line: |
In Vivo | Azathioprine (oral gavage, 25-400 mg/kg, everyday, 10days) sodium can affect bone marrow cells, red blood cells, and peripheral blood cytokines and other related parameters in a dose-dependent manner, and can induce apoptosis in female CD-1 mice and ICR mice[3]. Animal Model: |
Name | Azathioprine sodium |
CAS | 55774-33-9 |
Formula | C9H7N7NaO2S |
Molar Mass | 300.25 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. SoniaChavez-Alvarez, et al. Azathioprine: its uses in dermatology. An Bras Dermatol. 2020 Nov-Dec;95(6):731-736. [2]. Yue-Ting Wu, et al. Azathioprine hepatotoxicity and the protective effect of liquorice and glycyrrhizic acid. Phytother Res. 2006 Aug;20(8):640-5. doi: 10.1002/ptr.1920. [3]. Gemma Molyneux, et al. The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse. Int J Exp Pathol. 2008 Apr;89(2):138-58. |